gdc
Multiple MyelomaSlideshows

Multiple Myeloma

March is multiple myeloma month. Check out our slideshow on this cancer type.
Web Exclusives – March 28, 2017

  • Centers For Disease Control Co 768x512

    March is Multiple Myeloma Awareness Month. Here are some risk factors and statistics related to the disease.

  • Diverse Group 768x512

    In 2017, an estimated 30,280 new cases of multiple myeloma will be diagnosed, including 17,490 men and 12,790 women.

    Source: The American Cancer Society
  • Senior Couple On Bicycles 768x512

    Multiple myeloma is more than twice as common in African Americans as in white Americans.

    Source: The American Cancer Society
  • Mother Grown Son 768x512

    People who have a sibling or parent with multiple myeloma are 4 times more likely to have the disease.

    Source: The American Cancer Society
  • Mm Cells 768x512

    This disease is the second most common blood cancer in the world.

    Source: International Myeloma Foundation
  • Cq Logo

    To read more about multiple myeloma, check out our articles here.  

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
Darzalex Faspro Receives New FDA Indication, in Combination with Pomalyst and Dexamethasone, for the Treatment of Patients with Multiple Myeloma
In July 2021, the FDA approved a new indication for Darzalex Faspro (daratumumab and hyaluronidase-fihj), for use in combination with Pomalyst (pomalidomide) and dexamethasone, for adults with multiple myeloma who have received at least 1 previous line of therapy.
FDA Approvals, News & UpdatesMultiple Myeloma
Sarclisa Now Approved for Relapsed or Refractory Multiple Myeloma
In March 2021, the FDA approved a new indication for Sarclisa (isatuximab-irfc), in combination with Kyprolis and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma.
Last modified: October 3, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest